{
    "nct_id": "NCT05316701",
    "official_title": "A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft",
    "inclusion_criteria": "* Matched to a related or unrelated donor who is an 8/8 match for HLA-A, -B, -C, and DRB1\n* Diagnosed with one of the following diseases:\n\n  * Acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi), with or without the presence of known minimal residual disease\n  * Myelodysplastic syndromes (MDS) that are indicated for alloHSCT per 2017 International Expert Panel recommendations and/or have therapy-related/secondary MDS, with ≤ 10% blast burden in the bone marrow\n* Planned to undergo MA-alloHCT including one of the following myeloablative conditioning regimens:\n\n  * TBI/Cy\n  * TBI/Etoposide\n  * BFT\n* Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA)\n* Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%\n* Negative serum or urine beta-HCG test in females of childbearing potential\n* ALT/AST < 3 times ULN\n* Recipients in screening must screen negative for SARS-CoV-2 RNA using a PCR-based test\n* Disease Risk Index (DRI) overall risk categorization of intermediate or high\n* Total bilirubin ≤ upper limit of normal (ULN)\n* Estimated glomerular filtration rate (eGFR) ≥ 60 mL/minute\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Prior allogeneic HCT\n* Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.\n* Planned donor lymphocyte infusion (DLI)\n* Planned pharmaceutical in vivo or ex vivo T cell depletion\n* Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor\n* Karnofsky performance score < 70%\n* Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) > 4\n* Uncontrolled bacterial, viral or fungal infections at time of enrollment\n* Seropositive for HIV-1 or -2, HTLV-1 or -2, Hepatitis B sAg, Hepatitis C antibody\n* Known allergy or hypersensitivity to, or intolerance of, tacrolimus\n* Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal or Streptomyces avidinii proteins\n* Any uncontrolled autoimmune disease requiring active immunosuppressive treatment\n* Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected\n* Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care\n* Women who are pregnant or breastfeeding\n* Women of childbearing potential (WOCBP) or men who have sexual contact with WOCBP unwilling to use effective forms of birth control or abstinence for one year after transplantation",
    "miscellaneous_criteria": "Key"
}